F8 and hemophilia: Most patients (69.2%) received the factor concentrate on-demand as a current treatment option, which was lower than that reported in the DYNAMO study (98%), an international multicenter study including men aged 12 to 55 years with non-severe hemophilia (residual FVIII/IX activity: 2 to 35%) (21).